CASI
CASI Pharmaceuticals, Inc.NASDAQHealthcare$0.15+3.08%ClosedMarket Cap: $2.3M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.08
P/S
0.11
EV/EBITDA
-0.41
DCF Value
$-278.61
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
35.8%
Operating Margin
-168.0%
Net Margin
-183.9%
ROE
358.3%
ROA
-201.9%
ROIC
-1157.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $3.1M | 23.0% | $-10.7M | $-10.9M | $-0.68 | — |
| Q2 2025 | $4.2M | 49.3% | $-11.1M | $-13.4M | $-0.86 | — |
| Q1 2025 | $6.2M | 58.0% | $-10.4M | $-10.8M | $-0.69 | — |
| Q4 2024 | $13.4M | 24.2% | $-12.9M | $-14.4M | $-0.93 | — |
| FY 2024 | $28.5M | 39.1% | $-39.6M | $-39.3M | $-2.56 | — |
| Q3 2024 | $7.8M | 51.9% | $-8.5M | $-8.4M | $-0.55 | — |
| Q2 2024 | $4.0M | 51.9% | $-8.8M | $-7.0M | $-0.52 | — |
| Q1 2024 | $3.4M | 53.0% | $-9.2M | $-9.5M | $-0.71 | — |
| Q4 2023 | $6.9M | 59.0% | $-4.7M | $-6.1M | $-0.45 | — |
| FY 2023 | $33.9M | 59.2% | $-25.1M | $-26.9M | $-2.02 | — |
| Q3 2023 | $8.8M | 58.7% | $-5.1M | $-4.6M | $-0.35 | — |
| Q2 2023 | $9.8M | 59.4% | $-8.0M | $-10.2M | $-0.77 | — |